Sumitomo Pharma Co., Ltd.
4506.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥679,763,190 | ¥385,768,590 | ¥289,624,410 | ¥223,674,270 |
| - Cash | ¥38,490,000 | ¥20,453,000 | ¥23,116,000 | ¥85,393,000 |
| + Debt | ¥262,850,000 | ¥309,245,000 | ¥305,422,000 | ¥374,423,000 |
| Enterprise Value | ¥904,123,190 | ¥674,560,590 | ¥571,930,410 | ¥512,704,270 |
| Revenue | ¥119,120,000 | ¥108,002,000 | ¥105,649,000 | ¥112,434,000 |
| % Growth | 10.3% | 2.2% | -6% | – |
| Gross Profit | ¥73,531,000 | ¥63,890,000 | ¥65,978,000 | ¥70,995,000 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| EBITDA | ¥86,148,000 | ¥26,188,000 | ¥5,604,000 | ¥27,471,000 |
| % Margin | 72.3% | 24.2% | 5.3% | 24.4% |
| Net Income | ¥87,654,000 | ¥11,206,000 | ¥2,415,000 | ¥53,448,000 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS Diluted | 220.63 | 28.21 | 6.08 | 134.53 |
| % Growth | 682.1% | 364% | -95.5% | – |
| Operating Cash Flow | ¥18,217,000 | -¥192,000 | ¥11,009,000 | ¥939,000 |
| Capital Expenditures | -¥1,049,000 | -¥1,474,000 | -¥2,375,000 | -¥2,057,000 |
| Free Cash Flow | ¥17,168,000 | -¥1,666,000 | ¥8,634,000 | -¥1,118,000 |